Patents

US 11612615 B2: Combined administration of cysteine-aspartic protease inhibitors with P2Y12 receptor antagonists protects the heart against myocardial infarction

Granted
2023-03-28
Filed
2018-04-27 application 16608262
Type
Utility · 4 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y12 receptor antagonist or Glycoprotein IIb/IIIa inhibitor, the cysteine-aspartic protease inhibitor is selected from the group consisting of Caspase-1, 4, 5, 11 and 12 inhibitors, and reperfusion therapy is percutaneous coronary intervention. In certain embodiments, the at least one P2Y12 receptor antagonist is selected from the group consisting of cangrelor, ticagrelor, clopidogrel and prasugrel. The disclosed methods provide an improved cardioprotective effect against infarction when compared with the current standard of care.

Source: PVGPATDIS, file of 2026-04-10 (ipg230328.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
University of South Alabama 42 patentsUS company or organizationMobile, ALUniversity of South Alabama State business registration EXACT high confidence: identical full name and state
University of South Alabama College or university EXACT high confidence: identical full name and state
UNIVERSITY OF SOUTH ALABAMA Nonprofit EXACT high confidence: identical full name and state
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Jonathon P. AudiaMobile, AL1PVGPATDIS, file of 2026-04-10
James M. DowneyMobile, AL4PVGPATDIS, file of 2026-04-10
Diego AlvarezMobile, AL1PVGPATDIS, file of 2026-04-10
Michael V. CohenMobile, AL1PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/7076PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P9/10PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2023-02-03Assignment
Assignment of assignor's interest
AUDIA, JONATHON P. signed 2021-11-11
COHEN, MICHAEL V. signed 2021-11-11
DOWNY, JAMES M. signed 2021-11-11
ALVAREZ, DIEGO signed 2023-01-31
THE UNIVERSITY OF SOUTH ALABAMA MOBILE, AL62580/178ECORSEXC, file of 2026-09-25
2022-10-13Government interest
Confirmatory license
UNIVERSITY OF SOUTH ALABAMA signed 2022-07-30NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT BETHESDA, MD61670/628ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.